Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB01198_DB01319_nanopub.RAiexvHWmjdG6ffX3rAdKRhDVO1UMF4Wz6L5vOTc2XUcQ#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB01198_DB01319 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB01198_DB01319 label "DDI between Zopiclone and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if fosamprenavir is initiated, discontinued or dose changed. [drugbank_resource:DB01198_DB01319]" assertion.
- drugbank_resource:DB01198_DB01319 identifier "drugbank_resource:DB01198_DB01319" assertion.
- drugbank_resource:DB01198_DB01319 title "DDI between Zopiclone and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if fosamprenavir is initiated, discontinued or dose changed." assertion.
- drugbank:DB01198 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01198_DB01319 assertion.
- drugbank:DB01319 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB01198_DB01319 assertion.